- Home
- STKS vs ENTX Comparison
STKS vs ENTX Comparison
Compare STKS & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STKS
- ENTX
- Stock Information
- Founded
- STKS 2004
- ENTX 2010
- Country
- STKS United States
- ENTX Israel
- Employees
- STKS N/A
- ENTX 21
- Industry
- STKS Restaurants
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STKS Consumer Discretionary
- ENTX Health Care
- Exchange
- STKS Nasdaq
- ENTX Nasdaq
- Market Cap
- STKS 109.7M
- ENTX 91.3M
- IPO Year
- STKS N/A
- ENTX 2018
- Fundamental
- Price
- STKS $2.68
- ENTX $2.00
- Analyst Decision
- STKS Hold
- ENTX Strong Buy
- Analyst Count
- STKS 3
- ENTX 1
- Target Price
- STKS $4.50
- ENTX $10.00
- AVG Volume (30 Days)
- STKS 100.1K
- ENTX 294.0K
- Earning Date
- STKS 08-05-2025
- ENTX 08-08-2025
- Dividend Yield
- STKS N/A
- ENTX N/A
- EPS Growth
- STKS N/A
- ENTX N/A
- EPS
- STKS N/A
- ENTX N/A
- Revenue
- STKS $834,363,000.00
- ENTX $166,000.00
- Revenue This Year
- STKS $27.38
- ENTX N/A
- Revenue Next Year
- STKS $5.75
- ENTX N/A
- P/E Ratio
- STKS N/A
- ENTX N/A
- Revenue Growth
- STKS 96.64
- ENTX 191.23
- 52 Week Low
- STKS $2.37
- ENTX $1.50
- 52 Week High
- STKS $5.26
- ENTX $2.79
- Technical
- Relative Strength Index (RSI)
- STKS 31.22
- ENTX 54.00
- Support Level
- STKS $2.65
- ENTX $1.87
- Resistance Level
- STKS $3.19
- ENTX $2.14
- Average True Range (ATR)
- STKS 0.19
- ENTX 0.10
- MACD
- STKS -0.01
- ENTX 0.00
- Stochastic Oscillator
- STKS 9.99
- ENTX 60.00
About STKS The ONE Group Hospitality Inc.
The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through four segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.